Drugs / MTI-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06911008 | Nov 2025 → Apr 2027 expected | metastatic malignant neoplasm, refractory malignant neoplasm | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTI-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06911008 ↗ |
| Action | Inhibit | “MTI-301 is a drug that inhibits an enzyme called SCD1.” NCT06911008 ↗ |
| Route | Oral | “Patients receive MTI-301 orally (PO) once daily (QD) on days 1-28 of each cycle.” NCT06911008 ↗ |
| Target | SCD1 | “MTI-301 is a drug that inhibits an enzyme called SCD1.” NCT06911008 ↗ |